Hidradenitis Suppurativa Market
DelveInsight’s ‘Hidradenitis Suppurativa Market Insights, Epidemiology and Market Forecast-2030’ report delivers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.
The Hidradenitis Suppurativa market report provides current treatment practices, emerging drugs, Hidradenitis Suppurativa market share of the individual therapies, current and forecasted Hidradenitis Suppurativa market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Hidradenitis Suppurativa treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
Hidradenitis Suppurativa Epidemiology
The Hidradenitis Suppurativa epidemiology division provide the insights about historical and current Hidradenitis Suppurativa patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The total diagnosed incident cases of Hidradenitis Suppurativa (HS) patients were found to be more in females than in males in 7MM during the study period i.e. 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted Hidradenitis Suppurativa epidemiology [segmented as Total Prevalent Patient Population, Diagnosed Prevalent Patient Population, Age-specific Diagnosed Prevalent Patient Population, Gender-specific Diagnosed Prevalent Patient Population, Stage-Specific (Severity-specific) Prevalent Population, and Treated Prevalent Cases of HS] scenario of Hidradenitis Suppurativa in 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2017 to 2030.
Hidradenitis Suppurativa Drug Chapters
Drug chapter segment of the Hidradenitis Suppurativa report encloses the detailed analysis of Hidradenitis Suppurativa marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Hidradenitis Suppurativa clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Hidradenitis Suppurativa Marketed Drugs
Humira: AbbVie
Humira (Adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). This drug was created using phage display technology resulting in an antibody with human-derived heavy and light chain variable regions and human IgG1:k constant regions. It is produced by recombinant DNA technology in a mammalian cell expression system and is purified by a process that includes specific viral inactivation and removal steps.
Products detail in the report…
Hidradenitis Suppurativa Emerging Drugs
IFX-1: InflaRx
IFX-1 is a first-in-class monoclonal anti-complement factor C5a antibody, being developed by InflaRx for the treatment of patients with HS. It completely blocks biological activity and demonstrates high selectivity towards its target, C5a, in human blood. Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5.
Products detail in the report…
Cosentyx (Secukinumab): Novartis Pharmaceuticals
Cosentyx (Secukinumab) is an IL-17A monoclonal antibody that selectively binds to IL-17A and inhibits Interleukin-17A, and IL-17 promotes neutrophil activities and is marketed by Novartis. These cytokines act on many different cell types and provide defense against different extracellular pathogens causing fungal or bacterial infections.
Products detail in the report…
INCB054707: Incyte Corporation
INCB054707 is a selective JAK1 inhibitor, being developed by Incyte Corporation for the treatment of patients with Moderate-to-severe HS. This therapeutic molecule is administered by an oral route of administration. Currently, the company is investigating this molecule in the Phase II stage of development for HS.
Products detail in the report…
Bimekizumab: UCB Biopharma S.P.R.L
Bimekizumab is the first humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-17A and IL-17F, two key cytokines driving inflammatory processes. IL-17A and IL-17F are the most closely related members of the IL-17 family of cytokines.
Products detail in the report…
Bermekimab (MABp1): Janssen Pharmaceutical
MABp1 is a recombinant human IgG1 monoclonal antibody specific for human interleukin-1α, initially being developed by XBiotech for the treatment of patients with HS. Last year Jannsen pharmaceutical acquired rights for this product. It is the only antibody targeting IL-1a currently in clinical development and has the potential for superior efficacy and safety compared to the current standard of care.
Products detail in the report…
Hidradenitis Suppurativa Market Outlook
The Hidradenitis Suppurativa market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Hidradenitis Suppurativa market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of Hidradenitis Suppurativa market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The therapeutic market of Hidradenitis Suppurativa in seven major markets is expected to generate USD 798 million in 2017 and will increase in the study period 2017–2030.
Table of contents
1. Executive Summary: Hidradenitis Suppurativa (HS)
2. SWOT Analysis: Hidradenitis Suppurativa (HS)
3. Hidradenitis Suppurativa (HS) Patient Share (%) Overview at a Glance
3.1. Patient Share (%) Distribution of Hidradenitis Suppurativa in 2017 and 2030
4. Hidradenitis Suppurativa Market Overview at a Glance
4.1. Market Share (%) Distribution of Hidradenitis Suppurativa in 2017
4.2. Market Share (%) Distribution of Hidradenitis Suppurativa in 2030
5. Disease Overview: Hidradenitis Suppurativa (HS)
5.1. Introduction
5.2. Causes and Symptoms of Hidradenitis Suppurativa (HS)
5.3. Classification and Severity Assessment of Hidradenitis Suppurativa (HS)
5.3.1. Hurley Stages of HS
5.3.2. Modified Sartorius Score (MSS) of HS
5.3.3. Physician Global Assessment of Hidradenitis Suppurativa (HS-PGA)
5.3.4. Specific Severity Index of Hidradenitis Suppurativa (HSSI)
5.3.5. Pathophysiology of Hidradenitis Suppurativa
5.3.6. Genetic Basis of Hidradenitis Suppurativa (HS)
5.4. Diagnosis of Hidradenitis Suppurativa (HS)
5.4.1. Differential Diagnoses
5.4.2. Biomarkers of Hidradenitis Suppurativa (HS)
5.4.3. Risk Factors and Complications
5.4.4. Comorbidities
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Assumptions and Rationale: 7MM
6.3. Total Prevalent Patient Population of HS in the 7MM
6.4. Total Diagnosed Prevalent Patient Population of HS in the 7MM
6.5. Gender-Specific Prevalent Patient Population of HS in the 7MM
6.6. Age-Specific Prevalent Patient Population of HS in the 7MM
6.7. Stage-Specific (Severity-specific) prevalent cases of HS in the 7MM
6.8. Treated Prevalent Cases of HS in the 7MM
7. Country-wise Epidemiology of HS in the 7MM
7.1. United States
7.1.1. Total Diagnosed Prevalent cases of HS in the United States
7.1.2. Gender-Specific Prevalent cases of HS in the United States
7.1.3. Age-Specific Prevalent cases of HS in the United States
7.1.4. Stage-Specific Prevalent Cases of HS in the United States
7.1.5. Treated Prevalent Cases of HS in the United States
7.2. EU5
7.2.1. Germany
7.2.1.1. Total Diagnosed Prevalent cases of HS in Germany
7.2.1.2. Gender-Specific Prevalent cases of HS in Germany
7.2.1.3. Age-Specific Prevalent cases of HS in Germany
7.2.1.4. Stage-Specific Prevalent Cases of HS in Germany
7.2.1.5. Treated Prevalent Cases of HS in Germany
7.2.2. France
7.2.2.1. Total Diagnosed Prevalent cases of HS in France
7.2.2.2. Gender-Specific Prevalent cases of HS in France
7.2.2.3. Age-Specific Prevalent cases of HS in France
7.2.2.4. Stage-Specific Prevalent Cases of HS in France
7.2.2.5. Treated Prevalent Cases of HS in France
7.2.3. Italy
7.2.3.1. Total Diagnosed Prevalent cases of HS in Italy
7.2.3.2. Gender-Specific Prevalent cases of HS in Italy
7.2.3.3. Age-Specific Prevalent cases of HS in Italy
7.2.3.4. Stage-Specific Prevalent Cases of HS in Italy
7.2.3.5. Treated Prevalent Cases of HS in Italy
7.2.4. Spain
7.2.4.1. Total Diagnosed Prevalent cases of HS in Spain
7.2.4.2. Gender-Specific Prevalent cases of HS in Spain
7.2.4.3. Age-Specific Prevalent cases of HS in Spain
7.2.4.4. Stage-Specific Prevalent Cases of HS in Spain
7.2.4.5. Treated Prevalent Cases of HS in Spain
7.2.5. United Kingdom
7.2.5.1. Total Diagnosed Prevalent cases of HS in the United Kingdom
7.2.5.2. Gender-Specific Prevalent cases of HS in the United Kingdom
7.2.5.3. Age-Specific Prevalent cases of HS in the United Kingdom
7.2.5.4. Stage-Specific Prevalent Cases of HS in the United Kingdom
7.2.5.5. Treated Prevalent Cases of HS in the United Kingdom
7.3. Japan
7.3.1. Total Diagnosed Prevalent cases of HS in Japan
7.3.2. Gender-Specific Prevalent cases of HS in Japan
7.3.3. Age-Specific Prevalent cases of HS in Japan
7.3.4. Stage-Specific Prevalent Cases of HS in Japan
7.3.5. Treated Prevalent Cases of HS in Japan
8. Current Treatment Practices
8.1. European S1 Guideline for the Treatment of Hidradenitis Suppurativa/Acne Inversa
8.1.1. Medical therapy
8.1.2. Surgical therapy
8.2. North American Clinical Management Guidelines for HS
8.3. British Association of Dermatologists guidelines for the management of Hidradenitis Suppurativa (Acne Inversa) 2018
9. Patient Journey of Hidradenitis Suppurativa (HS)
10. Unmet Needs
11. Key Endpoints in Hidradenitis Suppurativa (HS) Clinical Trials
12. Marketed Drugs
12.1. Humira: AbbVie
12.1.1. Product Description
12.1.2. Regulatory milestones
12.1.3. Other developmental Activities
12.1.4. Pivotal Clinical Trials
12.1.5. Summary of Pivotal Clinical Trials
13. Emerging Therapies
13.1. Key Cross of Emerging Therapies
13.2. IFX-1: InflaRx
13.2.1. Product Description
13.2.2. Other developmental Activities
13.2.3. Clinical Development
13.2.4. Clinical Trials Information
13.2.5. Safety and Efficacy
13.3. Cosentyx (Secukinumab): Novartis Pharmaceuticals
13.3.1. Product Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.3.4. Clinical Trials Information
13.3.5. Safety and Efficacy
13.4. INCB054707: Incyte Corporation
13.4.1. Product Description
13.4.2. Clinical Development
13.4.3. Clinical Trials Information
13.5. CJM112: Novartis Pharmaceuticals
13.5.1. Product Description
13.5.2. Other developmental Activities
13.5.3. Clinical Development
13.5.4. Clinical Trials Information
13.5.5. Safety and Efficacy
13.6. Bimekizumab: UCB Biopharma S.P.R.L.
13.6.1. Product Description
13.6.2. Other developmental Activities
13.6.3. Clinical Development
13.6.4. Clinical Trials Information
13.7. Bermekimab (MABp1): Janssen Pharmaceutical
13.7.1. Product Description
13.7.2. Other Developmental Activities
13.7.3. Clinical Development
13.7.4. Clinical Trials Information
13.7.5. Safety and Efficacy
13.8. CFZ533 (Iscalimab) and LYS006: Novartis
13.8.1. Product Description
13.8.2. Other Developmental Activities
13.8.3. Clinical Development
13.8.4. Clinical Trials Information
13.9. Apremilast: Celgene
13.9.1. Product Description
13.9.2. Clinical Development
13.9.3. Clinical Trials Information
13.9.4. Safety and Efficacy
13.10. Avacopan: ChemoCentryx
13.10.1. Product Description
13.10.2. Other Developmental Activities
13.10.3. Clinical Development
13.10.4. Clinical Trials Information
13.11. PF-06650833, PF-06700841, and PF-06826647: Pfizer
13.11.1. Product Description
13.11.2. Clinical Development
13.11.3. Clinical Trials Information
13.12. Risankizumab: AbbVie
13.12.1. Product Description
13.12.2. Clinical Development
13.12.3. Clinical Trials Information
13.13. Guselkumab: Janssen Pharmaceutical
13.13.1. Product Description
13.13.2. Other Developmental Activities
13.13.3. Clinical Development
13.13.4. Clinical Trials Information
14. Attribute Analysis of Hidradenitis Suppurativa (HS) Therapies
15. Hidradenitis Suppurativa (HS): 7 Major Market Analysis
15.1. Key Findings
15.2. Market Size of Hidradenitis Suppurativa in 7MM
15.3. Market Size by therapies of Hidradenitis Suppurativa in 7MM
16. Market Outlook: 7MM
16.1. United States Market Size
16.1.1. Total Market size of Hidradenitis Suppurativa
16.1.2. Hidradenitis Suppurativa Market by Therapies
17. EU-5 Countries
17.1. Germany Market Size
17.1.1. Total Market size of Hidradenitis Suppurativa
17.1.2. Hidradenitis Suppurativa Market by Therapies
17.2. France Market Size
17.2.1. Total Market size of Hidradenitis Suppurativa
17.2.2. Hidradenitis Suppurativa Market by Therapies
17.3. Italy Market Size
17.3.1. Total Market size of Hidradenitis Suppurativa
17.3.2. Hidradenitis Suppurativa Market by Therapies
17.4. Spain Market Size
17.4.1. Total Market size of Hidradenitis Suppurativa
17.4.2. Hidradenitis Suppurativa Market by Therapies
17.5. United Kingdom Market Size
17.5.1. Total Market size of Hidradenitis Suppurativa
17.5.2. Hidradenitis Suppurativa Market by Therapies
18. Japan
18.1. Total Market size of Hidradenitis Suppurativa
18.2. Hidradenitis Suppurativa Market by Therapies
19. Market Access and Reimbursement Scenario of Hidradenitis Suppurativa (HS) Therapies
20. Market Drivers
21. Market Barriers
22. Appendix
22.1. Bibliography
22.2. Report Methodology
23. Disclaimer
24. DelveInsight Capabilities
25. About DelveInsight
Request for sample pages @ Hidradenitis Suppurativa Market Report
Media Contact
Company Name: DelveInsight
Contact Person: Media Relations
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/